Gyre Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Gyre Therapeutics, Inc. (GYRE) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $111.22 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2018-05-03
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-03-31 was $111.22M.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-12-31 was $11.34M, a 13565.06% increase year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-06-30 was $29.03M.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $35.40M, a 3634.18% increase from fiscal 2016.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $948.00K, a 89.82% decline from fiscal 2015.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $9.31M, a 86.00% increase from fiscal 2014.
- Gyre Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was $5.01M, a 12.80% decline from fiscal 2013.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $111.22M 10-Q · filed 2018-05-03 | $122.57M derived: sum of 2 quarters · filed 2018-05-03 | $122.57M derived: sum of 3 quarters · filed 2018-05-03 | $151.59M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-12-31 | $11.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $11.34M derived: sum of 2 quarters · filed 2018-03-19 | $40.37M derived: sum of 3 quarters · filed 2018-03-19 | $35.40M 10-K · filed 2018-03-19 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $29.03M derived: sum of 2 quarters · filed 2017-11-02 | $24.06M 10-Q · filed 2017-11-02 | $24.14M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-06-30 | $29.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $24.06M 10-Q · filed 2017-08-03 | $24.14M derived: sum of 3 quarters · filed 2018-05-03 | $24.85M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-03-31 | -$4.97M 10-Q · filed 2018-05-03 | $1.78M 10-Q · filed 2017-05-11 | -$4.89M derived: sum of 2 quarters · filed 2018-05-03 | -$4.18M derived: sum of 3 quarters · filed 2018-05-03 | ||||
| 2016-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $793.00K derived: sum of 2 quarters · filed 2018-03-19 | $948.00K 10-K · filed 2018-03-19 | |||||
| 2016-09-30 | $710.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $865.00K 10-Q · filed 2017-11-02 | ||||||
| 2016-06-30 | $155.00K 10-Q · filed 2017-08-03 | |||||||
| 2015-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $4.15M derived: sum of 2 quarters · filed 2017-03-08 | $6.03M derived: sum of 3 quarters · filed 2017-03-08 | $9.31M 10-K · filed 2017-03-08 | ||||
| 2015-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $5.86M derived: sum of 2 quarters · filed 2016-11-03 | $9.15M 10-Q · filed 2016-11-03 | $9.15M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $5.17M 10-Q · filed 2016-08-04 | -$39.00K 10-Q · filed 2015-07-31 | $5.17M derived: sum of 3 quarters · filed 2016-08-04 | $5.17M derived: sum of 4 quarters · filed 2016-08-04 | |||
| 2015-03-31 | $3.28M 10-Q · filed 2016-05-05 | $93.00K 10-Q · filed 2015-05-07 | $3.28M derived: sum of 2 quarters · filed 2016-05-05 | $3.29M derived: sum of 3 quarters · filed 2016-05-05 | $4.82M derived: sum of 4 quarters · filed 2016-05-05 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $4.00K derived: sum of 2 quarters · filed 2016-03-09 | $1.54M derived: sum of 3 quarters · filed 2016-03-09 | $5.01M 10-K · filed 2016-03-09 | $2.57M 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $4.00K derived: 10-Q 9 month − 8-K/A 6 month · filed 2015-11-05 | $1.54M derived: sum of 2 quarters · filed 2015-11-05 | $5.01M 10-Q · filed 2015-11-05 | $3.05M 10-Q · filed 2014-11-06 | $11.28M derived: sum of 4 quarters · filed 2016-03-09 | |||
| 2014-06-30 | $1.54M derived: 8-K/A 6 month − 10-Q 3 month · filed 2015-10-23 | $5.00M 8-K/A · filed 2015-10-23 | $3.27M 10-Q · filed 2015-07-31 | $11.28M derived: sum of 3 quarters · filed 2016-03-09 | ||||
| 2014-03-31 | $3.47M 10-Q · filed 2015-05-07 | $9.74M derived: sum of 2 quarters · filed 2016-03-09 | ||||||
| 2013-12-31 | $6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $5.74M 10-K · filed 2016-03-09 | -$552.00K 10-K · filed 2015-03-16 | |||||
| 2013-09-30 | -$530.00K 10-Q · filed 2014-11-06 | |||||||
| 2012-12-31 | -$626.00K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |